Home / Pharmaceuticals / Post-Traumatic Stress Disorder Therapeutics Market By Drug Class (Antidepressants, Anti-Anxiety Drugs, Other Drug Classes, Pipeline Candidate) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026

Post-Traumatic Stress Disorder Therapeutics Market By Drug Class (Antidepressants, Anti-Anxiety Drugs, Other Drug Classes, Pipeline Candidate) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026

Published: Apr 2018 | Report Code: 58727-04-18

Industry Outlook

The global post-traumatic stress disorder therapeutics market expected to reach 10,679.5 Mn by 2026 with CAGR of 4.5% during the forecast period from 2018 to 2026. Antidepressants including SSRIs (Zoloft and Paxil) are among the first line of treatment for PTSD, dominated the global market in 2017 and projected to retain its dominance during the forecast period. North America dominated the PTSD therapeutics market with more than 50% of market share for the year 2017. Higher awareness about healthcare and treatment among the general population, better rate of self-reporting are some macro factors contributing to the dominance of North America in the global market. Post-traumatic stress disorder (PTSD) is a vastly prevalent disorder but a rarely recognized syndrome that is characterized by some serious reactions such as fear, helplessness, and horror. According to the Diagnostic and Statistical Manual of Mental Disorders, PTSD is categorized as acute if symptoms are within three months of the trauma, and chronic if symptoms occur between three to six months of the trauma.

Post-traumatic stress disorder is classified as anxiety disorder and symptoms of PTSD can develop either immediately following a traumatic event or during the course of time. The symptoms of PTSD comprise abnormal mood swings, avoidance of stressful incidents and so on. PTSD occurs at any age, irrespective of gender; however, the prevalence of PTSD is higher in women. As reported by PTSD United, an estimated one in every eight women develops PTSD in a lifetime, thus making females twice more likely than males. The prevalence of PTSD in the United States is 3.5%.

Growing prevalence of post-traumatic stress disorder is the chief factor driving global post-traumatic stress disorder drugs market. Increase in events such as wars, combats, and interpersonal violence has been a major contributor to the growing prevalence of PTSD. Factors such as growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

The United States dominated the global PTSD therapeutics market. Moreover, the domicile of prominent players and swift approval of drugs in the region ensures the dominance of North America. Europe is identified as the second largest market due to the growing patient pool, greater awareness regarding availability and efficacy of therapeutics, and initiatives from government and non-government organizations to strengthen and develop healthcare infrastructure along with favorable reimbursement system. The awareness related to PTSD is low in the Asia Pacific compared to North America & Europe due to lack of diagnosis and criticality of mental disorders in general public.  

Market Synopsis

Post-Traumatic Stress Disorder Therapeutics Market

Antidepressant drugs leading the post-traumatic stress disorder therapeutics market

Currently, antidepressants including SSRIs (Zoloft and Paxil) are among the first line of treatment for PTSD, dominated the global market in 2017 and projected to retain its dominance during the forecast period from 2018 to 2026. Moreover, the prevalence of diseases is rising due to the increasing number of accidents and violence worldwide the global PTSD therapeutics market is expected to grow during the forecast period from 2018 to 2026.

Post-Traumatic Stress Disorder Therapeutics Market

Post-Traumatic Stress Disorder Therapeutics Market

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

This comprehensive study offers the analysis of every segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded Annual Growth Rate (CAGR) for each segment calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Post-traumatic stress disorder therapeutics market study offers the existing market dynamics along with a quantitative analysis of the global market. The report elucidates the detailed outline of global post-traumatic stress disorder therapeutics market by classifying the market in terms of drug class and geography. The objective of publishing this extensive research report is to support the healthcare professionals and market investors in making strategic initiatives and better conclusions in the post-traumatic stress disorder therapeutics market.

Drug Class Segment (2016–2026; US$ Mn)

  • Antidepressants
    • SSRIs
    • SNRIs
    • MAO Inhibitors
    • Tricyclic Antidepressants
  • Anti-anxiety Drugs
    • Beta-blockers
    • Benzodiazepines
  • Other Drug Class
    • Alpha-1 & Alpha-2 Receptor Antagonists
    • Atypical Antipsychotics
    • Anticonvulsants
  • Pipeline Candidates (Qualitative information)
    • SRX 246 (Phase II)
    • BNC 210 (Phase II)
    • Tonmya (Phase II)
  • Geography Segment (2016–2026; US$ Mn)
    • North America
      • United States
      • Canada
    • Europe
      • United Kingdom
      • Germany
      • Rest of Europe
    • Asia Pacific (APAC)
      • Japan
      • China
      • Rest of APAC
    • Latin America (LATAM)
      • Mexico
      • Brazil
      • Rest of LATAM
    • Middle East and Africa (MEA)
      • GCC
      • Rest of Middle East and Africa

Post-Traumatic Stress Disorder Therapeutics Market

This comprehensive study further describes the major qualitative market assessment factors including main market drivers, market trends, and restraints, to help in better understanding of global post-traumatic stress disorder therapeutics market. Every market assessment factor including market drivers, challenges, and opportunities are widely explained considering the existing market situation. This study fully maps the market players based on their strategies, market initiatives, business strength, and product offering. Moreover, the report offers attractive investment proposal based on the widespread geographical research. Main players profiled in the study include Pfizer, Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd, Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc., Bionomics Ltd., Tonix Pharmaceuticals Holding Corp., Apotex, Inc. among others.

Key questions answered in this report

  • What are the current market trends in the post-traumatic stress disorder therapeutics market and valued opportunities for the players?
  • How the regulatory framework affects the global as well as the regional markets?
  • Which is the prominent drug class in PTSD treatment market?
  • How does the FDA approval of products affect the global market?
  • What are the trend and market size in emerging markets such as Japan, Mexico, and Brazil?
  • Which is the largest and fastest growing regional market?
  • Which is the largest segment by drug class in the post-traumatic stress disorder therapeutics market?
  • Which is the fastest growing segment by drug class in the post-traumatic stress disorder therapeutics market?
  • Market assessment in terms of value.
  • Analysis of market strategies and competitive landscapes.

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2017 (US$ Mn)
2.2. Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Post-Traumatic Stress Disorder Therapeutics Market Overview, 2016 - 2026 (US$ Mn)
3.1. Overview
3.2. Market Drivers
3.2.1. Growing Events of Violence and Wars
3.3. Challenges
3.3.1. Lack of Timely Diagnosis and Access to Care
3.3.2. Risk of Side Effects
3.4. Opportunities
3.4.1. Promising Pipeline Candidates
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Market Competition Assessment, 2017

Chapter 4. Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Antidepressants
4.2.1. SSRIs
4.2.2. SNRIs
4.2.3. MAO Inhibitors
4.2.4. Tricyclic Antidepressants
4.3. Anti-anxiety Drugs
4.3.1. Beta-blockers
4.3.2. Benzodiazepines
4.4. Other Drug Classes
4.4.1. Alpha-1 & Alpha-2 Receptor Antagonists
4.4.2. Atypical Antipsychotics
4.4.3. Anticonvulsants
4.5. Pipeline Candidates (Qualitative Information)
4.5.1. SRX 246 (Phase II)
4.5.2. BNC 210 (Phase II)
4.5.3. Tonmya (Phase II)

Chapter 5. Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America
5.2.1. North America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.2.3. North America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.2.4. North America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.2.5. North America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.2.5.1. U.S.
5.2.5.2. Canada
5.3. Europe
5.3.1. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.3.3. Europe Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.3.4. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.3.5. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.3.5.1. U.K.
5.3.5.2. Germany
5.3.5.3. Rest of Europe
5.4. Asia Pacific
5.4.1. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.4.3. Asia Pacific Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.4.4. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.4.5. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.4.5.1. Japan
5.4.5.2. China
5.4.5.3. Rest of APAC
5.5. Latin America
5.5.1. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.5.3. Latin America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.5.4. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.5.5. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.5.5.1. Brazil
5.5.5.2. Mexico
5.5.5.3. Rest of Latin America
5.6. Middle East & Africa
5.6.1. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.6.3. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.6.4. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.6.5. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Region, 2016 – 2026 (US$ Mn)
5.6.5.1. GCC
5.6.5.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Pfizer, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. GlaxoSmithKline plc
6.3. Otsuka Pharmaceutical Co., Ltd
6.4. Novartis AG
6.5. AstraZeneca Plc
6.6. Azevan Pharmaceuticals, Inc.
6.7. Bionomics Ltd.
6.8. Tonix Pharmaceuticals Holding Corp.
6.9. Apotex, Inc.

FIG. 1 Global Post-Traumatic Stress Disorder Therapeutics Market: Research Methodology
FIG. 2 Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2017 (US$ Mn)
FIG. 3 Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2017 (US$ Mn)
FIG. 4 Annual Number of Deaths in Combatants, 1945 to 2010
FIG. 5 Attractive Investment Proposition: Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2017
FIG. 6 Competitive Landscape, by Key Players, 2017
FIG. 7 Global SSRIs Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 8 Global SNRIs Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 9 Global MAO Inhibitors Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 10 Global Tricyclic Antidepressants Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 11 Global Beta-Blockers Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 12 Global Benzodiazepines Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 13 Global Alpha-1 & Alpha-2 Receptor Antagonists Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 14 Global Atypical Antipsychotics Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 15 Global Anticonvulsants Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)

TABLE 1 Global Post-Traumatic Stress Syndrome Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 2 Global Antidepressants Market for Post-Traumatic Stress Syndrome, 2016–2026 (US$ Mn)
TABLE 3 Global Anti-anxiety Drugs Market for Post-Traumatic Stress Syndrome, 2016–2026 (US$ Mn)
TABLE 4 Global Other Drug Classes Market for Post-Traumatic Stress Syndrome, 2016–2026 (US$ Mn)
TABLE 5 Global Post-Traumatic Stress Syndrome Therapeutics Market, by Geography, 2016–2026 (US$ Mn)
TABLE 6 North America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 7 North America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 8 North America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 9 North America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 10 North America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 11 Europe Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Europe Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 13 Europe Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 14 Europe Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 15 Europe Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 16 Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 17 Asia Pacific Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 18 Asia Pacific Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 19 Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 20 Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 21 Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 22 Latin America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 23 Latin America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 24 Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 25 Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 26 Middle East & Africa Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 27 Middle East & Africa Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 28 Middle East & Africa Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 29 Middle East & Africa Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 30 Middle East & Africa Post-Traumatic Stress Disorder Therapeutics Market, by Region, 2016–2026 (US$ Mn)
TABLE 31 Pfizer, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 32 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 33 Otsuka Pharmaceutical Co., Ltd.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 34 Novartis AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 35 AstraZeneca Plc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 36 Azevan Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 37 Bionomics Ltd.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 38 Tonix Pharmaceuticals Holding Corp.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 39 Apotex Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients